Robert Clarke - Pulmatrix Insider

PULM -- USA Stock  

USD 0.53  0.019747  3.59%

CEO and President and Director
Dr. Robert W. Clarke, Ph.D., is Chief Executive Officer and Director of the Company. Dr. Clarke has served as our chief executive officer and director since June 15, 2015, and he was the chief executive officer and director of Pulmatrix Operating since July 2012. Dr. Clarke joined Pulmatrix Operating in April 2004 as its first Ph.D. scientist and served as Chief Scientific Officer from May 2011 to September 2012, where he oversaw the research and development efforts focused on the iCALM and iSPERSE technologies. Prior to joining our Company, Mr. Clarke served as an Associate Director of Life Sciences at Alkermes, Inc. focusing on the development of inhaled therapeutic products based on the Advanced Inhalation Research technology. Dr. Clarke holds a B.Sc. in Biomedical Engineering from Boston University and received his Ph.D. in Physiology from Johns Hopkins University
Age: 46  CEO Since 2015  Ph.D    
Clarke also completed postdoctoral training in Respiratory Biology at Brigham and Women?s Hospital and Harvard University. As a result of Dr. Clarke?s more than twenty years of experience in the healthcare industry and his focus on pulmonary drug delivery and the role of inhaled particles in respiratory biology and medicine, including coauthorship of over eighty chapters, papers, and abstracts, we believe that Dr. Clarke is qualified to serve as a member of the Board.

Robert Clarke Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (65.98) % which means that it has lost $65.98 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (168.96) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 2.52 M in liabilities with Debt to Equity (D/E) ratio of 33.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Pulmatrix has Current Ratio of 0.32 indicating that it has a negative working capital and may not be able to pay financial obligations when they are due.

Similar Executives

Found 11 records

CEO Since

Ron EllisEndocyte
Barry SimonNantKwest
Rui ArashiyamaChina Cord Blood Corporation
Douglas FambroughDicerna Pharmaceuticals
Jeffrey BachaDelMar Pharmaceuticals
Brian LeuthnerEdge Therapeutics
Eddie GrayDynavax Technologies Corporatio
Yue DengChina Cord Blood Corporation
Ryan WattsDenali Therapeutics
Ting ZhengChina Cord Blood Corporation
Alex SapirDova Pharmaceuticals

Entity Summary

Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted technology. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts. Pulmatrix operates under Biotechnology classification in USA and traded on NASDAQ General Markets. It employs 24 people.Pulmatrix (PULM) is traded on BATS Exchange in USA. It is located in MASSACHUSETTS U.S.A and employs 24 people. Pulmatrix was previously known as PULMATRIX INC and was traded on BATS Exchange under the symbol RTGN. Pulmatrix is listed under Pharmaceutical Products category by Fama And French industry classification.

Pulmatrix Leadership Team

Terrance McGuire, Director, MBA
Matthew Sherman, Director
David Hava, Executive, Ph.D
Akihisa Akao, Director
James Roach, Executive, Ph.D
Michael Higgins, Director, MBA
Steven Gillis, Director
Jean Sung, President
William Duke, CFO, MBA
Robert Clarke, CEO, Ph.D
Scott Rocklage, Director, Ph.D
Kurt Graves, Director
Richard Conley, Director, MBA
Mark Iwicki, Chairman, MBA
Amit Munshi, Director, MBA
Gregory French, Director
David JD, Executive

Stock Performance Indicators

Current Sentiment - PULM

Pulmatrix Investor Sentiment
Most of Macroaxis users are at this time bullish on Pulmatrix. What is your perspective on investing in Pulmatrix? Are you bullish or bearish?
98% Bullish
2% Bearish
Currently Active Assets on Macroaxis
Purchased over 100 shares of
few hours ago
Traded for 25.35
Purchased over 500 shares of
few hours ago
Traded for 5.66
Purchased few shares of
few hours ago
Traded for 1188.8199
Purchased over 70 shares of
few hours ago
Traded for 39.36
Purchased few shares of
few hours ago
Traded for 1188.8199
Additionally take a look at Your Equity Center. Please also try Cryptocurrency Correlation module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins and exchanges.